Frontage's Biomarker Services group provides comprehensive biomarker assay development, validation, and sample analysis support for pharmaceutical, biotechnology, and academic clients across a broad range of therapeutic areas, including oncology, neuroscience, immunology, inflammation, metabolic diseases, and rare diseases. Our scientists have employed state-of-the-art technologies including NULISA, SIMOA, MSD, Luminex, Ella, ELISA, LC-MS/MS, and other emerging ultra-sensitive detection platforms to deliver high-quality biomarker data that enable critical drug development decisions.